Jeanne Palmer, MD Mayo Clinic, Arizona

Similar documents
Myelodysplastic syndrome. Jeanne Palmer, MD Mayo Clinic, Arizona

Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ

Current Prognostication in Primary Myelofibrosis

The Evolving Role of Transplantation for MPN

Mayo Clinic Treatment Strategy in Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis 2013 Update

ASBMT MDS/MPN Update Sunil Abhyankar, MD

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:

Hematopoietic Cell Transplantation for Myelofibrosis. Outline

CLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98

Myeloproliferative Disorders - D Savage - 9 Jan 2002

Should Intermediate-I risk PMF be transplanted immediately or later? Position: Later

JAKAFI (ruxolitinib phosphate) oral tablet

Let s Look at Our Blood

Intro alla patologia. Giovanni Barosi. Fondazione IRCCS Policlinico San Matteo Pavia

5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA

Classical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis. Francesco Passamonti Università degli Studi dell Insubria, Varese

An Introduction to Bone Marrow Transplant

Stifel Nicolaus 2013 Healthcare Conference. John Scarlett, M.D. Chief Executive Officer September 11, 2013

Disclosures for Ayalew Tefferi

Mielofibrosi: inquadramento dei fattori prognostici

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

An Overview of US-Based MPN Guidelines: A First Look

7/24/2017. MDS: Understanding Your Diagnosis and Current and Emerging Treatments. Hematopoiesis = Blood Cell Production

Polycytemia Vera, Essential Thrombocythemia and Myelofibrosis: prognosis and treatment

JAK2 Inhibitors for Myeloproliferative Diseases

Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017

Table 1: biological tests in SMD

Heme 9 Myeloid neoplasms

Myeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:

Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM

Preliminary Results From a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis

Transplants for MPD and MDS

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

CHALLENGING CASES PRESENTATION

J Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION

Polycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi

Treating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS

By Angela Gascoigne Haematology CNS Chesterfield Royal Hospital

Recommended Timing for Transplant Consultation

Acute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg

Chronic Lymphocytic Leukemia (CLL)

ASBMT MDS/MPN UPDATE

London Cancer. Myelofibrosis guidelines. August Review August Version v1.0. Page 1 of 12

Chronic myelomonocytic leukemia. Lymphoma Tumor Board. May 26, 2017

Leukemia and subsequent solid tumors among patients with myeloproliferative neoplasms

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data

Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP

Transplantation for Myeloproliferative neoplasms in the JAK inh era PARAMESWARAN HARI MEDICAL COLLEGE OF WISCONSIN MILWAUKEE

PRM 151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks

MDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?

Glossary of Blood, MPN, and Mutation Terms

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University

OVERALL CLINICAL BENEFIT

JAK inhibitors in Phmyeloproliferative

Acute Lymphoblastic and Myeloid Leukemia

MPNs: JAK2 inhibitors & beyond. Mohamed Abdelmooti (MD) NCI, Cairo University, Egypt

HCT for Myelofibrosis

Nicole Laferriere MD PhD FRCPC April 10, Patient Case Studies: Sticky Situations For Platelet Transfusions

UNDERSTANDING MYELOFIBROSIS (MF) A guide for patients and caregivers

New Therapies for MPNs

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

Disclosures for Ayalew Tefferi

Acute Leukemia Diagnosis

Chronic Myelomonocytic Leukemia with molecular abnormalities SH

Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms

OneMatch Stem Cell and Marrow Network. Training Guide

Unmet Medical Needs in Myelofibrosis

Practical Considerations in the Treatment Myeloproliferative Neoplasms: Prognostication and Current Treatment Indy Hematology

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD

Bone Marrow Transplantation

How I Treat Myelofibrosis. Adam Mead, MD, PhD University of Oxford Oxford, United Kingdom

Myelodysplastic Syndrome: Let s build a definition

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms

N Engl J Med Volume 373(12): September 17, 2015

HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Part 4 MYELOID NEOPLASMS

Technical Bulletin No. 100

HEMATOLOGIC MALIGNANCIES BIOLOGY

Lymphomas: Current Therapy Approaches

Management of Multiple Myeloma: The Changing Paradigm

Myelodysplastic Syndromes (MDS) Diagnosis, Treatments & Support

Evolving Management of Myelofibrosis

Evolving Guidelines of MPNs Where do new options fit in your treatment plan?

Juvenile Myelomonocytic Leukemia (JMML)

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization

Understanding & Treating Myelodysplastic Syndrome (MDS)

HSCT for Myeloproliferative Disorders. Jane Apperley

Case Workshop of Society for Hematopathology and European Association for Haematopathology

Disclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms

Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome

The Changing Face of MDS: Advances in Treatment

74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow

2013 AAIM Pathology Workshop

Diagnosing and Treating Myeloproliferative Neoplasms

[COMPREHENSIVE GENETIC ASSAY PANEL ON

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease

Research Article Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib

New and Emerging Strategies in the Treatment of Patients with Higher risk Myelodysplastic Syndromes (MDS)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA) Ruxolitinib for the treatment of myelofibrosis

Post-ASH 2015 CML - MPN

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Transcription:

Setting the stage for Transplant in MPN Jeanne Palmer, MD Mayo Clinic, Arizona

What will be covered What is a bone marrow transplant? When to start thinking about bone marrow transplant Timing of transplant Understanding disease risk

Bone marrow transplantation Involves high dose/intermediate dose chemotherapy followed by hematopoietic stem cell infusion. Chemotherapy helps reduce disease + suppress immune system New blood system works better New stem cells fight off underlying disease graft versus myelofibrosis Autologous: uses patients own stem cells, allows use of high dose chemotherapy Allogeneic : uses donor stem cells, either related or unrelated

Alternative names Alternative names: Peripheral blood stem cell transplant Hematopoietic stem cell transplant Bone marrow transplant Bone marrow vs peripheral blood Refers to how the hematopoietic stem cells are collected: Bone marrow: through bone marrow harvest, a procedure performed in the OR Peripheral blood collection: collected after giving neupogen via leukopheresis

Leukopheresis

How does transplant work Conditioning http://biomed.brown.edu/courses/bi108/bi108_2007_groups/group07/s temcells/img/allogenic_big.gif

WHY WOULD I WANT TO DO THIS TO MYSELF? SHOULD I PURSUE A CLINICAL TRIAL INSTEAD?

What are common concerns about transplant? Survey done on patients with MPN Less than half the patients were referred for transplant Of those who saw a transplant specialist, less than half planned on proceeding with transplant due to the following concerns Quality of life Financial implications Caregiver Graft versus host disease WHY?? Further studies ongoing to understand the thought process around transplant

Other considerations Physicians are human and have biases as well Transplant physicians Hematologists Blogs Everyone experiences transplant differently People like to share their experiences

Clinical trials and medical treatment There are good clinical trials and treatments in MF No curative options yet This is a very individualized decision

When do I see a transplant specialist? Important to see a transplant specialist early in the disease course even if you aren t sure whether you will proceed with transplant or not Understand and plan for the different resources needed for transplant Caregiver Financial Lodging Understand the process of transplant Have time to process all the information related to transplant

Who should I see? Helpful to see a transplant specialist who has knowledge regarding transplants for MF The timing of transplant is a SHARED decision making process There is no one answer that is correct for anyone Even if you don t get a transplant at the center, good to have the discussion/opinion

What to expect during a bone marrow transplant consultation Bring a family member/friend Be prepared to be scared If you can, record the consultation If you have any doubts get a second opinion

So, when should I get a transplant? Generally transplant is reserved for higher risk patients It is important to KNOW YOUR RISK Can be dependent on life events

HOW DO WE DEFINE RISK?

Dynamic International Prognostic Scoring System DIPSS scores/risk: 0 pts: low risk 1-2 pts: Intermediate 1 3-4 pts: Intermediate 2 5-6 pts: High risk (2 pts) DIPSS plus scores/risk 0 pts: low risk 1 pt: intermediate-1 2-3 pts: intermediate-2 4-6 pts: high risk

Clarification of risks Anemia low red blood cell count. Hemoglobin (hgb) is consistently less than 10 Thrombocytopenia- low platelet (plt) count, less than 100. Leukocytosis high white blood cell count (WBC), consistently greater than 25 Blasts immature white blood cells Note this does not mean you have leukemia unless blast % greater than 20% Abnormal karyotype Constitutional symptoms- fatigue, weight loss, decreased appetite, night sweats

Stem cell transplant spectrum timing tool This tool uses DIPSS score to give a sense of when a transplant should be considered Even in the case of low risk disease- good to start the conversation http://www.mpntransplant.com/

When to think about a transplant DIPSS low risk or Int-1 risk DIPSS Int-2 risk DIPSS High risk, advanced disease with organ dysfunction Diagnosis of disease

When to do transplant Too early! DIPSS low risk or Int-1 risk Just right DIPSS Int-2 risk Too late! DIPSS High risk, advanced disease with organ dysfunction Diagnosis of disease

Other factors that contribute to risk Driver mutation Cytogenetics Molecular mutations

Driver mutation Mutations that CAUSE the disease JAK-2 MPL CAL-R CAL-R is GOOD No mutations is unfavorable

Cytogenetics Cytogenetics (abnormal chromosomes found in your bone marrow) complex karyotype (3 or more abnormalities) or sole or 2 abnormalities that include +8, 7/7q, i(17q), inv(3), 5/5q, 12p, or 11q23 rearrangement These are not inherited they are changes that occur only in disease cells

Molecular mutations next generation sequencing

Good news The disadvantages of high risk disease are usually overcome with transplant!!

When to do transplant Too early! DIPSS low risk or int-1 risk Just right Too late! High risk, advanced disease with organ dysfunction? Bad risk chromosomes /mutations Good risk mutations

Other considerations Symptom burden Ruxolitinib (Jakafi ) Transfusion dependence What gives you points??

Example #1 64 year old patient with primary myelofibrosis CAL-R positive On 1/5/19 WBC 23K, 2% blasts, hgb 9.7, platelets 115 (DIPSS: 3) On 2/5/19 WBC 26K, 0 blasts, hgb 10.2, platelets 150 (DIPSS: 1) Would this change if JAK2 positive? ASXL1 positive?

Example #2 Patient is 58 year old female with post-essential thrombocythemia myelofibrosis MPL positive Hgb 7, requires transfusion every month, WBC 6.7, Blasts 0 DIPSS: 2

Example #3 65 year old male with primary myelofibrosis JAK2 positive Hgb 9.5, WBC 7.2, blasts 0, platelets 165 DIPSS: 3

Summary Bone marrow transplant is a curative option for myelofibrosis When the best time to undergo transplant is still under investigation Know your risk! The risk of disease as characterized by cytogenetics, molecular mutations etc

Survivors